Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.
about
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision makingRandomised trials in surgery: problems and possible solutions.Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.An evaluation of bicalutamide in the treatment of prostate cancer.Herbal supplement PC-Spes for prostate cancer.Risk stratification in the hormonal treatment of patients with prostate cancerSix-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases.Prostate cancer and the principles of hormone therapy.Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.Overcoming drug resistance and treating advanced prostate cancerSurgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapyClinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonistsEarly and delayed castrations confer a similar survival advantage in TRAMP miceMortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studiesSerially heterotransplanted human prostate tumours as an experimental modelProstate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs.Evidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate.LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer.Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis.Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer.Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population.Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.Management of the side effects of androgen deprivation therapy in men with prostate cancer
P2860
Q26739738-359FD22C-047E-4F6A-8B13-9EC9DD20EFF3Q27022847-1DE393DC-1213-4884-B29C-BD875A226054Q27025062-0FA974B6-5454-4441-AF02-A3E14253F06EQ30475881-BBF2FFC3-ED0B-400F-B700-DBE98FD1A6C7Q33637134-13916504-9A6F-4A4E-8498-15BFD48444A7Q33803812-4EDCA40D-F4AE-4756-ACAD-5B8189FCFEFBQ33977523-C15FBADD-E741-4DD0-A6FD-96349038EC6EQ34145167-8BD8B4E7-2C8E-4F6D-BC5F-877438BB82ACQ34615655-E3C81708-E615-49D8-A719-A280C6604882Q35076189-0B480A36-FF92-4E17-B4E4-B3E60D4FED6AQ35161023-D6285922-9CA4-409B-9B43-6F4140AE4ED1Q35689824-0E627562-281F-4A16-92A4-6B0AB23F44A7Q35879087-37A8E590-8F9C-4E07-A38C-EAA66DB65AA9Q36082100-D6B7F398-A271-4A49-9237-AD6DA56F6BCBQ36143973-A1B21E62-746C-4785-9B69-5D1D66B13AE2Q36173646-45D5FA15-6341-4C34-A6AB-444F6EA9677BQ36328812-25C9E6B4-8308-495F-B497-ABB10095DDD9Q36387830-C41B12C4-6931-44B2-B1A0-EF2DD60EF762Q36833751-B9C33E15-5663-4F35-BF7A-F913CE7D6F43Q37074958-5880D9C8-414E-4746-80B5-001A5D1A9837Q37205661-F35554F6-B2EF-452B-9E21-772241725EF8Q37310963-B3C0DF3E-7E14-4B1E-969E-6FA97C622ED9Q37390104-CB49A31A-BFAA-4024-BD3C-5B54C75E21D5Q37478907-5DA1DD2D-FFF3-4A07-9F49-E1D3996A828BQ37809569-E1DBB916-43D6-479B-B422-80B21D8B790FQ39831515-21951E6C-9465-4317-BE33-08A347C9CF22Q41094726-36ADAF9F-680A-4698-8430-90731C10E510Q42139750-2BF83C8A-A93C-4DEF-892A-7C4927D0B648Q43509250-7461C3FD-4590-49E4-BE60-E61C505B2852Q44703733-CE70DF64-1286-412E-8BBF-2E8D15BCBA23Q45256738-2F76A6D7-6D19-4793-9411-F58E18B8B595Q47610526-0AC4F4B8-E052-4C2D-B591-3E63173C6C4FQ51315083-8846F214-CB06-4985-BEC0-5ECD854AB19AQ53548387-272D15D8-0C42-4CAD-AE81-52EA8E01FC36Q57143367-C57F9C95-DDCF-42BF-BADB-EEB1BBD15E44
P2860
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Goserelin versus orchiectomy i ...... Zoladex Prostate Study Group.
@en
Goserelin versus orchiectomy i ...... Zoladex Prostate Study Group.
@nl
type
label
Goserelin versus orchiectomy i ...... Zoladex Prostate Study Group.
@en
Goserelin versus orchiectomy i ...... Zoladex Prostate Study Group.
@nl
prefLabel
Goserelin versus orchiectomy i ...... Zoladex Prostate Study Group.
@en
Goserelin versus orchiectomy i ...... Zoladex Prostate Study Group.
@nl
P2093
P1433
P1476
Goserelin versus orchiectomy i ...... Zoladex Prostate Study Group.
@en
P2093
Kennealey GT
Schellhammer PF
Smith JA Jr
Soloway MS
Vogelzang NJ
P304
P356
10.1016/S0090-4295(99)80197-6
P407
P577
1995-08-01T00:00:00Z